Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection

OBJECTIVES: Fidaxomicin was non-inferior to vancomycin with respect to clinical cure rates in the treatment of Clostridium difficile infections (CDIs) in two Phase III trials, but was associated with significantly fewer recurrences than vancomycin. This economic analysis investigated the cost-effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Nathwani, Dilip, Cornely, Oliver A., Van Engen, Anke K., Odufowora-Sita, Olatunji, Retsa, Peny, Odeyemi, Isaac A. O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195473/
https://www.ncbi.nlm.nih.gov/pubmed/25096079
http://dx.doi.org/10.1093/jac/dku257

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195473/
https://www.ncbi.nlm.nih.gov/pubmed/25096079
http://dx.doi.org/10.1093/jac/dku257

Ejemplares similares